GenTide is building the AI-native infrastructure for drug discovery — a platform that compounds in value with every experiment, every target, every partnership. 睿联生物正在构建 AI-Native 的药物发现基础设施——一个随着每次实验、每个靶点、 每次合作而持续增值的平台。
GenTide is structured for both near-term validation and long-term platform value. Each successful partnership enhances the DTBL platform; each pipeline advance de-risks the next licensing deal. 睿联的架构兼顾近期验证与长期平台价值。每次成功合作都增强 DTBL 平台； 每条管线的推进都为下一个授权交易降低风险。
In-house models (NBI, SGEDiff, ComplexDnet) built on published research from the founding team — not wrapped APIs. A deep moat that grows with every training run. 基于创始团队已发表研究的自研模型（NBI、SGEDiff、ComplexDnet）， 而非 API 封装。随每次训练持续加深的竞争壁垒。
In-house cryo-EM closes the experimental loop in days, not months — giving GenTide a structural data advantage that CRO-dependent competitors cannot replicate. 内部冷冻电镜将实验闭环从数月压缩至数天——为睿联建立依赖外部 CRO 的竞争对手无法复制的结构数据优势。
Nav1.8 selective inhibitor program targets the $15B+ non-opioid pain market with a first-in-class profile — positioned as a near-term License-out asset with global big pharma. Nav1.8 选择性抑制剂项目以同类首创特性切入 150 亿美元以上的非阿片类镇痛市场， 定位为与全球大药企的近期授权资产。
Founded AI-native from day one — no legacy workflows, no IT debt, no organizational inertia. This structural advantage cannot be acquired; it can only be built at the start. 从第一天起就 AI-Native 建立——没有遗留工作流、IT 负债或组织惯性。 这一结构优势无法后天获得，只能在起点建立。
Founders with track records at Agios Pharmaceuticals (Tibsovo®), ECUST, Nature Aging, and industry-standard computational tools adopted globally. Science credibility from day one. 创始人来自 Agios Pharmaceuticals（Tibsovo®）、华东理工大学、《自然·衰老》 及全球广泛采用的计算工具。从第一天起就具备科学公信力。
The β2-AR anti-aging program addresses one of the largest emerging therapeutic frontiers — healthy aging for a global aging population — with a novel mechanism backed by Nature Aging data. β2-AR 抗衰老项目指向全球最大新兴治疗领域之一——以《自然·衰老》数据支撑的 新型作用机制，面向全球老龄化人口的健康老龄化需求。
Large pharma partnerships where GenTide's DTBL platform accelerates partners' internal discovery programs. Fee-for-service and milestone-based structures. Near-term revenue with platform validation. 为大型药企提供 DTBL 平台赋能，加速其内部发现项目。 采用服务费用与里程碑组合结构。实现平台商业验证的近期收入。
License-out of GenTide's proprietary pipeline programs (Nav1.8 as primary near-term asset) to global pharma upon reaching clinical-stage milestones. Upfront payments, milestones, and royalties. 将睿联自研管线（以 Nav1.8 为近期首要资产）在达到临床阶段里程碑后 对外授权给全球药企，获取首付款、里程碑款和版权费。
Regional partnership structures where GenTide co-develops select programs with regional strategic partners (Asia-Pacific, Middle East) in exchange for rights and equity participation. 与亚太、中东等区域战略伙伴联合开发特定项目， 以换取权益和股权参与。
We welcome conversations with investors, strategic partners, and pharma companies interested in the AIDD space. Reach out to our business development team for an initial discussion. 欢迎对 AIDD 领域感兴趣的投资者、战略合作伙伴与大药企与我们洽谈。 请联系我们的业务拓展团队开始初步沟通。
Contact Business Development 联系业务拓展团队Disclaimer: This page contains forward-looking statements about GenTide's business, strategy, and pipeline programs. These statements involve risks and uncertainties and should not be relied upon as guarantees of future performance. Drug discovery is subject to clinical, regulatory, and commercial risks. This page does not constitute an offer to sell or solicitation of an offer to buy any securities. 免责声明：本页面包含有关睿联生物业务、战略及管线项目的前瞻性陈述。 这些陈述涉及风险与不确定性，不应被视为对未来业绩的保证。药物发现面临临床、 监管及商业风险。本页面不构成出售证券的要约或购买证券的邀请。